Akila Srinivasan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Akila Srinivasan has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Sandhiya Selvarajan
Department of Clinical Pharmacology JIPMER Puducherry India
2 shared publications Arunmozhy S.
Pharmacovigilance Associate, Department of Clinical Pharmacology, JIPMER, Pondicherry, India
1 shared publication- Barathane Datchanamurthy
Department of Pharmacology , Mahatma Gandhi Medical College and Research Institute (MGMCRI), Sri Balaji Vidyapeeth (Deemed-to be-University) , Pondicherry , India
1 shared publication - Kannan Manivel
Department of Pharmacology , PPG College of Pharmacy , Saravanampatti , Coimbatore , India
1 shared publication Nakka Chandrasekhar Prasanna Lakshmi
Directorate of Indian System of Medicine, Govt. of Puducherry, Puducherry, India
1 shared publicationSadishkumar Kamalanathan
Department of Endocrinology, JIPMER, Puducherry, India
1 shared publication
Latest Publications
- Open Access
- 12 May 2026
- Published by Walter de Gruyter GmbH in Journal of Complementary and Integrative Medicine
Phytochemical profiling and cytotoxic potential of hydroalcoholic extract of Begonia malabarica in HepG2 cells: an in vitro phytopharmacological study
Objectives: In this study, the hydroalcoholic extract of entire Begonia malabarica plant was screened to identify its specific phytochemical groups and in vitro cytotoxic potential against HepG2 (Human Hepatocellular carcinoma) cell lines. Methods: Annexin V/PI Apoptotic assay and the MTT assay, were employed in this study. MTT assay was used to evaluate in vitro cytotoxic potential of B. malabarica extract against the HepG2 cell line. The Annexin V/PI Apoptotic assay was performed to estimate the proportion of cells undergoing apoptosis. The results were compared with doxorubicin as standard. Results: The MTT assay found that at highest concentration of 500 μg/mL, the hydroalcoholic extract of B. malabarica reduced cell viability to 24.17 %, while doxorubicin treated cell showed cell viability to 4.8 % at highest concentration of 100 μg/mL. Flow cytometry based Annexin V analysis revealed that B. malabarica extract induced pronounced apoptosis in HepG2 cells, marked by a dominant late apoptotic population (70.56 %) and dead cells (22.17 %), with minimal early apoptotic (0.04 %) and viable cells (7.23 %). The percentage of cells undergone late apoptosis was identical to standard drug doxorubicin (71.2 %). These results suggest a late apoptotic response, potentially involving mitochondrial disruption, oxidative stress, or caspase activation. Conclusions: These findings highlight the presence of bioactive compounds in B. malabarica that can modulate cell death pathways, supporting its potential as a potential anti-cancer agent. However, more research can help in better understanding of the role of this plant as a potential new source of cancer therapy and uncover previously unknown pharmacological activities and properties.
- 12 May 2026
- Published by Walter de Gruyter GmbH in Journal of Complementary and Integrative Medicine
Open AccessPhytochemical profiling and cytotoxic potential of hydroalcoholic extract of Begonia malabarica in HepG2 cells: an in vitro phytopharmacological study
Objectives: In this study, the hydroalcoholic extract of entire Begonia malabarica plant was screened to identify its specific phytochemical groups and in vitro cytotoxic potential against HepG2 (Human Hepatocellular carcinoma) cell lines. Methods: Annexin V/PI Apoptotic assay and the MTT assay, were employed in this study. MTT assay was used to evaluate in vitro cytotoxic potential of B. malabarica extract against the HepG2 cell line. The Annexin V/PI Apoptotic assay was performed to estimate the proportion of cells undergoing apoptosis. The results were compared with doxorubicin as standard. Results: The MTT assay found that at highest concentration of 500 μg/mL, the hydroalcoholic extract of B. malabarica reduced cell viability to 24.17 %, while doxorubicin treated cell showed cell viability to 4.8 % at highest concentration of 100 μg/mL. Flow cytometry based Annexin V analysis revealed that B. malabarica extract induced pronounced apoptosis in HepG2 cells, marked by a dominant late apoptotic population (70.56 %) and dead cells (22.17 %), with minimal early apoptotic (0.04 %) and viable cells (7.23 %). The percentage of cells undergone late apoptosis was identical to standard drug doxorubicin (71.2 %). These results suggest a late apoptotic response, potentially involving mitochondrial disruption, oxidative stress, or caspase activation. Conclusions: These findings highlight the presence of bioactive compounds in B. malabarica that can modulate cell death pathways, supporting its potential as a potential anti-cancer agent. However, more research can help in better understanding of the role of this plant as a potential new source of cancer therapy and uncover previously unknown pharmacological activities and properties.
- 1 August 2025
- Published by Bentham Science Publishers Ltd. in Current Drug Safety
- Vol. 20 (3) , 349-360
A Retrospective Observational Study of Adverse Drug Reactions (ADR) Reported to ADR Monitoring Centre from 2010 to 2020
Background: Adverse Drug Reactions (ADR) are one of the common causes of hospital admissions and pose a significant clinical and economic burden on the healthcare system. The Adverse Drug Reaction Monitoring Centre (AMC) in JIPMER functioning under the Pharmacovigilance Programme of India (PvPI) plays a vital role in ensuring medication safety by routinely detecting and monitoring ADRs. Hence, this study aimed to assess the characteristics of ADR reported from 2010 to 2020 in AMC JIPMER and to detect signals, if any. Materials and Methods: A total of 6007 ADR reports with a single suspect drug were included for analysis from 2010 to 2020. The characteristics of these reports, including patient’s age and gender, Number and percentage of ADRs, the causality of ADR using WHO UMC (World Health Organization-Uppsala Monitoring Centre) scale, the seriousness of the ADR, and outcome were collected from the ADR reports. MedDRA (Medical Dictionary for Regulatory Activities) Preferred Terms (PT) were used to classify adverse drug reactions. Causality analysis using the Naranjo Algorithm and Preventability using Modified Schumock and Thornton criteria were performed for the ADRs. The number and percentage of severe ADRs were analyzed. The System Organ class of all the ADRs was enumerated. ADRs not mentioned in the US FDA (United States Food and Drug Administration) product label (unlabelled reactions) were documented. Unlabeled reactions with ≥3 ADR reports were included for signal detection by disproportionality analysis. Objective: To study the characteristics of Adverse Drug Reactions (ADR) reported to a regional ADR monitoring center from 2010 to 2020 and to detect signals of disproportionate reporting (SDRs) if any from the reported ADRs. Results: Antineoplastic drugs, followed by antimicrobials, anticonvulsants, Anti snake venom, and NSAID were the most common drugs implicated in ADRs. Skin and subcutaneous tissue disorders were the most common System Organ Class (SOC) involved in the ADRs. Among the 6007 reports, 19.2% were serious ADRs. Most of the ADR reports were of possible causality followed by probable and certain as per WHO UMC and Naranjo causality scales. Only ten ADRs were preventable and one reaction (Tamoxifen-induced neuropathy) was eligible for signal detection. Disproportionality analysis using a 2x2 contingency table showed insignificant signal detection using the Reporting Odds Ratio (ROR) and Proportional Reporting Ratio (PRR). Conclusion: Analysis of ADRs from an ADR Monitoring center functioning in a tertiary care hospital shows antineoplastic drugs to be the most common drugs associated with adverse drug reactions, with rash being the most common adverse effect. The majority of the ADRs were not preventable. No Signals of Disproportionate Reporting (SDR) were detected in our study.
- 1 August 2025
- Published by Bentham Science Publishers Ltd. in Current Drug Safety
- Vol. 20 (3) , 349-360
A Retrospective Observational Study of Adverse Drug Reactions (ADR) Reported to ADR Monitoring Centre from 2010 to 2020
Background: Adverse Drug Reactions (ADR) are one of the common causes of hospital admissions and pose a significant clinical and economic burden on the healthcare system. The Adverse Drug Reaction Monitoring Centre (AMC) in JIPMER functioning under the Pharmacovigilance Programme of India (PvPI) plays a vital role in ensuring medication safety by routinely detecting and monitoring ADRs. Hence, this study aimed to assess the characteristics of ADR reported from 2010 to 2020 in AMC JIPMER and to detect signals, if any. Materials and Methods: A total of 6007 ADR reports with a single suspect drug were included for analysis from 2010 to 2020. The characteristics of these reports, including patient’s age and gender, Number and percentage of ADRs, the causality of ADR using WHO UMC (World Health Organization-Uppsala Monitoring Centre) scale, the seriousness of the ADR, and outcome were collected from the ADR reports. MedDRA (Medical Dictionary for Regulatory Activities) Preferred Terms (PT) were used to classify adverse drug reactions. Causality analysis using the Naranjo Algorithm and Preventability using Modified Schumock and Thornton criteria were performed for the ADRs. The number and percentage of severe ADRs were analyzed. The System Organ class of all the ADRs was enumerated. ADRs not mentioned in the US FDA (United States Food and Drug Administration) product label (unlabelled reactions) were documented. Unlabeled reactions with ≥3 ADR reports were included for signal detection by disproportionality analysis. Objective: To study the characteristics of Adverse Drug Reactions (ADR) reported to a regional ADR monitoring center from 2010 to 2020 and to detect signals of disproportionate reporting (SDRs) if any from the reported ADRs. Results: Antineoplastic drugs, followed by antimicrobials, anticonvulsants, Anti snake venom, and NSAID were the most common drugs implicated in ADRs. Skin and subcutaneous tissue disorders were the most common System Organ Class (SOC) involved in the ADRs. Among the 6007 reports, 19.2% were serious ADRs. Most of the ADR reports were of possible causality followed by probable and certain as per WHO UMC and Naranjo causality scales. Only ten ADRs were preventable and one reaction (Tamoxifen-induced neuropathy) was eligible for signal detection. Disproportionality analysis using a 2x2 contingency table showed insignificant signal detection using the Reporting Odds Ratio (ROR) and Proportional Reporting Ratio (PRR). Conclusion: Analysis of ADRs from an ADR Monitoring center functioning in a tertiary care hospital shows antineoplastic drugs to be the most common drugs associated with adverse drug reactions, with rash being the most common adverse effect. The majority of the ADRs were not preventable. No Signals of Disproportionate Reporting (SDR) were detected in our study.
- 2 June 2019
- Published by Wiley in Phytotherapy Research
- Vol. 33 (7) , 1898-1911
Effect of Curcuma longa on vascular function in native Tamilians with type 2 diabetes mellitus: A randomized, double‐blind, parallel arm, placebo‐controlled trial
Diabetes mellitus is characterized by increased central arterial stiffness and endothelial dysfunction leading to increased risk of cardiovascular complications. The aim of this study is to evaluate the effect of Curcuma longa on arterial stiffness and endothelial dysfunction in patients with type 2 diabetes mellitus. This randomized controlled trial was conducted in 136 patients of type 2 diabetes. Among them, 114 completed at least one follow‐up visit and included for data analysis. Arterial stiffness parameters were measured at baseline and every month for 3 months and endothelial dysfunction markers at baseline and after 3 months of treatment with C. longa or placebo. These parameters were compared between the two groups. Both C. longa and placebo groups were comparable at baseline. After 3 months of treatment, C. longa produced significant reduction from baseline in carotid–femoral pulse wave velocity (p = .002), left brachial–ankle pulse wave velocity (p = .001), aortic augmentation pressure (p = .007), aortic augmentation index (p = .007), and aortic augmentation index at heart rate 75 (p = .018) as compared with the placebo group. Three months treatment with C. longa significantly decreases arterial stiffness as compared with placebo in type 2 diabetes mellitus patients.
- 2 June 2019
- Published by Wiley in Phytotherapy Research
- Vol. 33 (7) , 1898-1911
Effect of Curcuma longa on vascular function in native Tamilians with type 2 diabetes mellitus: A randomized, double‐blind, parallel arm, placebo‐controlled trial
Diabetes mellitus is characterized by increased central arterial stiffness and endothelial dysfunction leading to increased risk of cardiovascular complications. The aim of this study is to evaluate the effect of Curcuma longa on arterial stiffness and endothelial dysfunction in patients with type 2 diabetes mellitus. This randomized controlled trial was conducted in 136 patients of type 2 diabetes. Among them, 114 completed at least one follow‐up visit and included for data analysis. Arterial stiffness parameters were measured at baseline and every month for 3 months and endothelial dysfunction markers at baseline and after 3 months of treatment with C. longa or placebo. These parameters were compared between the two groups. Both C. longa and placebo groups were comparable at baseline. After 3 months of treatment, C. longa produced significant reduction from baseline in carotid–femoral pulse wave velocity (p = .002), left brachial–ankle pulse wave velocity (p = .001), aortic augmentation pressure (p = .007), aortic augmentation index (p = .007), and aortic augmentation index at heart rate 75 (p = .018) as compared with the placebo group. Three months treatment with C. longa significantly decreases arterial stiffness as compared with placebo in type 2 diabetes mellitus patients.